The aim of the current project is to validate whether chronic intake (24 weeks) roflumilast
(PDE4 inhibitor) can improve cognition in clinical patients with mild cognitive impairment
(MCI). The project will demonstrate whether episodic memory, but also attention, information
processing or executive function improves with chronic administration of roflumilast in MCI
patients.